Calidi Biotherapeutics Q3 2026 net loss attributable to common stockholders narrows 67% to $3.6 million

• Calidi Biotherapeutics’ third-quarter 2026 net loss attributable to common stockholders narrowed 67% year-over-year to $3.6 million.
• General and administrative expenses fell 39% year-over-year to $1.6 million, while research and development spending rose 13% to $2.7 million.
• Cash declined 30% to $3.9 million at September 30, 2026, from December 31, 2025.
• A November 6 restructuring, predominantly through headcount reductions, is expected to save $3 million annually and extend operating runway.
• Lead candidate CLD-401 continued progressing toward the clinic, with preclinical data showing complete tumor eradication in 80% of breast cancer tumor-bearing mice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-460816), on November 13, 2026, and is solely responsible for the information contained therein.